09.20.06
Caprion Pharmaceuticals completed Phase I studies for Shigamabs, its product for the treatment of Shigatoxin-producing E. coli infections (STEC), including the O157:H7 strain involved in the current U.S. outbreak. The severe clinical symptoms such as hemorrhagic colitis, thrombocytopenia, hemolytic anemia and hemolytic uremic syndrome in as many as 60% of all infected patients, are potentially lethal in the most severe cases. Serious complications are most frequent in young children and the elderly. There are no treatments currently available for STEC infections.
The safety and tolerability of the company's anti-toxin antibodies were evaluated in 40 healthy adult volunteers. Shigamabs were shown to be safe and well tolerated in three studies conducted over the last four years at major medical centers in the U.S. and Canada.
Caprion is planning a Shigamabs trial in the EU and North America in 2007 pending final regulatory review.
The safety and tolerability of the company's anti-toxin antibodies were evaluated in 40 healthy adult volunteers. Shigamabs were shown to be safe and well tolerated in three studies conducted over the last four years at major medical centers in the U.S. and Canada.
Caprion is planning a Shigamabs trial in the EU and North America in 2007 pending final regulatory review.